7月3日，礼邦医药-B盘中上涨7.92%，报28.8港元/股，成交额472.29万港元。
礼邦医药成立于2018年，是一家专注肾脏疾病领域的生物制药企业，拥有覆盖高磷血症、肾性贫血、IgA肾病、糖尿病肾病等多适应症的产品管线。核心产品AP301为治疗高磷血症的口服磷结合剂，已完成中国III期注册临床试验，预计近期提交新药上市申请，目前正在中美推进全球III期关键多中心临床试验。公司于6月29日以22.60港元/股的发行价登陆港交所，上市首日收涨103.54%。
（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.